ikr

Dimethindene (Dimetindeno) is a selective antagonist of H1 receptor and blocks K+ current. Dimethindene exhibits antihistamine and anticholinergic effects.

Phe-Met-Arg-Phe, amide acetate, activates a K+ current in peptidergic caudodorsal neurons dose-dependently (ED50=23 nM) and appears to localize with neuropeptide Y in some brain regions.

Nifekalant hydrochloride is an IKr potassium channel blocker with an IC50 of 10 µM. It is a Class III antiarrhythmic compound and can be used in the study of tachyarrhythmias.

Sematilide hydrochloride (CK-1752) is a class III antiarrhythmic. It is a selectively delayed rectifier K+ current (IKr) channel blocker. It inhibits rapidly activating Ik in guinea pig atrial myocytes, resulting in the prolongation of refractoriness and action potential duration.

Plasma kallikrein-IN-5 (Compound 20) is an effective covalent inhibitor of plasma kallikrein (Pka), with an IC50 of 66 nM at 1 minute and 70 pM at 24 hours. It is used in research related to hereditary angioedema (HAE).

Kallikrein5-IN-2 TFA is the trifluoroacetate salt form of Kallikrein5-IN-2. It acts as a selective inhibitor of kallikrein5 (KLK5), with a pIC50 value of 7.1. Kallikrein5-IN-2 TFA exhibits no phototoxicity at 100 μg/mL and is non-irritating. The compound remains stable in non-oxidative conditions within a pH range of 4 to 8. Kallikrein5-IN-2 shows potential for improving Netherton syndrome.

Plasma kallikrein-IN-1 is a PKK inhibitor with an IC50 value of 0.5 nM.

Plasma kallikrein-IN-3, a potent inhibitor ( IC 50 : 0.15 μM) of plasma kallikrein, finds application in research related to hereditary angioedema, diabetic macular edema, and diabetic retinopathy [1].

Kallikrein-IN-1 (Formula A) is an inhibitor of the kinin-releasing enzyme kallikrein.

Kallikrein-IN-2 (compound 1) is an inhibitor of the kinin-releasing enzyme Kallikrein.

Plasma kallikrein-IN-2, a potent inhibitor of plasma kallikrein (PKal) with an inhibitory concentration (IC) 50 value of 0.1 nM, is utilized in research targeting hereditary angioedema, diabetic macular edema, and diabetic retinopathy.

Kallikrein 5-IN-2 is a potent inhibitor of Kallikrein KLK5, exhibiting selectivity with a pIC50 value of 7.1. By inhibiting KLK5, it has the potential to normalize epidermal shedding, thereby reducing associated inflammation and itching.

Kallikrein is capable of forming the kallikrenase kalinin system (KKS) in plasma and tissues, producing bradykinin and kalin peptides , respectively [1] .

Anti-KLK5/Kallikrein 5 Antibody is a human-derived antibody expressed in CHO cells, targeting KLK5/Kallikrein 5. It features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For the isotype control, refer to HumanIgG1kappa, Isotype Control.

HumanKallikrein is a serine protease found in both plasma and tissues. It has the potential to be studied for its roles in regulating blood pressure, activating the complement system, and mediating and sustaining inflammatory responses.

Aprotinin (Traskolan) is a broad-spectrum serine protease (BPTI) inhibitor that inhibits the activity of a number of different esterases and proteases. Aprotinin is an antifibrinolytic agent used to minimize hemorrhage during complex surgical procedures.

Ranolazine dihydrochloride (Ranolazine 2HCl) , an antianginal agent, can treat arrhythmia via a novel mechanism of action (inhibition of the late phase of the inward sodium current), and do not affect blood pressure or heart rate.

Ranolazine (RS 43285-003) is a calcium uptake inhibitor via the sodium/calcium channel, used to treat chronic angina. It affects the sodium-dependent calcium channels during myocardial ischemia in rabbits by altering the intracellular sodium level.

IDO1-IN-19 (Compound 17) is a potent IDO1 inhibitor with potential applications in cancer research.

LSP-249 is a plasma kallikrein inhibitor under the study for angioedema, with an EC50 less than 100 nM in cell.

Avoralstat (BCX4161) is an oral plasma kallikrein (PKK) inhibitor. Which is used for the treatment of hereditary angioedema.

Picromycin is a 14-membered macrolide antibiotic and Prolyl endopeptidase (PREP) inhibitor. Pikromycin shows activity against gram-positive bacteria including mycobacteria.

SSR-182289A (Free) is a thrombin inhibitor.

Sebetralstat (KVD900) is an inhibitor of plasma kallikrein and can be used in studies about metabolic diseases.